FCER2 and metabolic dysfunction-associated steatohepatitis: In these settings, B-cell activation appears an early event in NASH [35,37], as the onset of experimental NASH is accompanied by a significant expansion of the fraction of CD43−/CD23+ B2-cells that contribute to hepatic inflammation by producing pro-inflammatory cytokines such as TNF-α and IL-6.